Melfalan Sun (Melphalan)

Melphalan works by forming covalent cross‑links between DNA strands, which blocks DNA replication and transcription. This disruption triggers programmed cell death (apoptosis) in malignant cells that are actively dividing, while sparing most normal, non‑proliferating tissues.

The specific dose of melphalan is determined by the prescribing oncologist based on the patient’s diagnosis, body surface area, renal function and treatment protocol. Dosing regimens vary widely and are individualized for each patient.

Melphalan is classified as potentially harmful to the fetus and is generally contraindicated during pregnancy unless the therapeutic benefit justifies the risk. Breastfeeding is not recommended while receiving melphalan because the drug can be excreted in milk and may affect the infant.

To order Melfalan Sun, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Melphalan belongs to the same class as cyclophosphamide and chlorambucil but differs in its chemical structure and potency. It is often preferred for certain hematologic cancers such as multiple myeloma because of its demonstrated efficacy, whereas other alkylators may be chosen based on toxicity profile, disease type or combination regimen.

Melfalan Sun should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use and handled using aseptic technique to maintain sterility during preparation and administration.

Melfalan Sun is administered by intravenous infusion under the supervision of qualified healthcare professionals. The infusion rate and duration are determined by the treatment protocol, and patients are monitored for infusion‑related reactions and vital signs throughout the procedure.

The most serious risks include severe myelosuppression leading to infection or bleeding, secondary leukemia, aplastic anemia, pulmonary toxicity, and renal impairment. Patients should be closely monitored with regular blood tests and clinical assessments to detect these complications early.

Melphalan should be avoided in patients with known hypersensitivity to alkylating agents, severe renal or hepatic dysfunction, active uncontrolled infections, and in pregnant or nursing women unless absolutely necessary. It is also contraindicated in individuals receiving live vaccines during therapy.